Enhanced Ga2O3-photocatalyzed and photochemical degradation of the Fipronil insecticide by UVC irradiation in mixed aqueous/organic media under an inert atmosphere.

Agrochemicals such as the insecticide Fipronil that bear fluoro groups are generally fat-soluble and nearly insoluble in water, so that their photodegradation in a heterogeneous aqueous gallium oxide dispersion presents some challenges. This article examined the photodegradation of this insecticide by solubilizing it through the addition of organic solvents (EtOH, MeOH, THF, 1,4-dioxane and ethylene glycol) to an aqueous medium and then subjecting the insecticide to 254 nm UVC radiation under photocatalytically inert (Ga2O3/N2) and air-equilibrated (Ga2O3/O2) conditions, as well as photochemically in the absence of Ga2O3 but also under inert and air-equilibrated conditions. Defluorination, dechlorination, desulfonation and denitridation of Fipronil were examined in mixed aqueous/organic media (10, 25 and 50 vol% in organic solvent).

Photoassisted defluorination of fluorinated substrates and pharmaceuticals by a wide bandgap metal oxide in aqueous media.

Persistent fluorinated substances, such as the fluorine-bearing pharmaceutical drugs Fluoxetine (FLX; Prozac) and Fluvoxamine maleate (FOM) together with several other substrates (fluorobenzoic acid and fluoroaliphatic model compounds), were photochemically defluorinated and degraded under UVC illumination in relatively good yields in the presence of a wide band gap metal oxide (β-Ga2O3) in heterogeneous aqueous media. The formation of fluoride ions increased with increasing illumination time under an inert nitrogen atmosphere, the transformation of the aromatic moiety was slower under these conditions, but nonetheless it did occur. The optimal amount of β-Ga2O3 loading for defluorination was 50 mg in aqueous media (0.

Efficacy and safety of milnacipran in the treatment of generalized anxiety disorder: an open study.

OBJECTIVE The aim of this open study was to assess the efficacy and safety of the serotonin-noradrenaline reuptake-inhibiting antidepressant, milnacipran, for the treatment of generalised anxiety disorder. METHODS Twelve patients, treated with milnacipran at doses from 30 to 150 mg/day for 8 weeks, were evaluated at baseline and after 1, 2, 3, 4, 6 and 8 weeks of treatment using the Hamilton Anxiety Rating (HAM-A) scale and a self-rating visual analogue scale. RESULTS Two patients dropped out early in the trial because of adverse effects.